Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017, Article ID 9561013, 4 pages
https://doi.org/10.1155/2017/9561013
Case Report

Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review

1Division of Internal Medicine of the Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
2Division of Hematology Oncology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
3Hematology Section, Medical Service, Veterans Affairs Medical Center, Washington, DC, USA
4Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
5Pathology and Laboratory Medicine Service, Veterans Affairs Medical Center, Washington, DC, USA

Correspondence should be addressed to Geraldine P. Schechter; vog.av@rethcehcS.enidlareG

Received 16 June 2017; Accepted 17 August 2017; Published 24 September 2017

Academic Editor: Ramon Tiu

Copyright © 2017 Hind Rafei et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. J. Delecluse, I. Anagnostopoulos, F. Dallenbach et al., “Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection,” Blood, vol. 89, no. 4, pp. 1413–1420, 1997. View at Google Scholar · View at Scopus
  2. C.-C. Chang, X. Zhou, J. J. Taylor et al., “Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma,” Journal of Hematology and Oncology, vol. 2, article 47, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Stein, N. Harris, and E. Campo, “Plasmablastic lymphoma,” in WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, S. Swerdlow, E. Campo, N. Harris et al., Eds., pp. 256-257, IARC, Lyon, France, 2008. View at Google Scholar
  4. J. J. Castillo, E. S. Winer, D. Stachurski et al., “HIV-negative plasmablastic lymphoma: not in the mouth,” Clinical Lymphoma, Myeloma and Leukemia, vol. 11, no. 2, pp. 185–189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. J. Liu, L. Zhang, E. Ayala et al., “Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review,” Leukemia Research, vol. 35, no. 12, pp. 1571–1577, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Castillo, L. Pantanowitz, and B. J. Dezube, “HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases,” American Journal of Hematology, vol. 83, no. 10, pp. 804–809, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J. J. Castillo, M. Furman, B. E. Beltrán et al., “Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy,” Cancer, vol. 118, no. 21, pp. 5270–5277, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. J. Castillo, E. S. Winer, D. Stachurski et al., “Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma,” The Oncologist, vol. 15, no. 3, pp. 293–299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. W. H. Wilson, M. L. Grossbard, and S. Pittaluga, “Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy,” Blood, vol. 99, no. 8, pp. 2685–2693, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Diamond, T. H. Taylor, T. Im, and H. Anton-Culver, “Presentation and outcomes of systemic non-Hodgkin's lymphoma: A comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS,” Leukemia and Lymphoma, vol. 47, no. 9, pp. 1822–1829, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Spina, A. Carbone, E. Vaccher et al., “Outcome in Patients with Non-Hodgkin Lymphoma and With or Without Human Immunodeficiency Virus Infection,” Clinical Infectious Diseases, vol. 38, no. 1, pp. 142–144, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Schommers, M. Hentrich, and C. Hoffmann, “Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort,” British Journal of Haematology, vol. 168, no. 6, pp. 806–810, 2015. View at Publisher · View at Google Scholar
  13. S. Loghavi, K. Alayed, T. N. Aladily et al., “Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: A clinicopathologic analysis of 61 patients,” Journal of Hematology and Oncology, vol. 8, no. 1, article no. 65, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Tchernonog, P. Faurie, P. Coppo et al., “Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: Analysis of 135 patients from the lysa group,” Annals of Oncology, 2016. View at Google Scholar
  15. I. F. Ibrahim, G. A. Shapiro, and H. V. K. Naina, “Treatment of HIV-associated plasmablastic lymphoma: A single-center experience with 25 patients,” Journal of Clinical Oncology, 8583, pp. 32–35, 2014. View at Google Scholar
  16. National Comprehensive Cancer Network. NCCN Guidelines Version 4.2014: AIDS-related B-cell lymphoma. AIDS-3.
  17. C. C. Pinnix, J. J. Shah, H. Chuang et al., “Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review,” Clinical Lymphoma, Myeloma and Leukemia, vol. 16, no. 3, pp. 122–128, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. A. A. Alizadeh, M. B. Eisen, R. E. Davis et al., “Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling,” Nature, vol. 403, no. 6769, pp. 503–511, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Rosenwald, G. Wright, WC. Chan et al., “The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma,” The New England Journal of Medicine, vol. 346, no. 25, p. 47, 1937. View at Google Scholar
  20. K. Dunleavy, S. Pittaluga, M. S. Czuczman et al., “Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma,” Blood, vol. 113, no. 24, pp. 6069–6076, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. J. J. Castillo, J. L. Reagan, W. M. Sikov, and E. S. Winer, “Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma,” British Journal of Haematology, vol. 169, no. 3, pp. 352–355, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. P. L. Fedele, G. P. Gregory, M. Gilbertson et al., “Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma,” Annals of Hematology, vol. 95, no. 4, pp. 667-668, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. B. M. Holderness, S. Malhotra, N. B. Levy, and A. V. Danilov, “Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 31, no. 12, pp. e197–e199, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Pretscher, A. Kalisch, M. Wilhelm, and J. Birkmann, “Refractory plasmablastic lymphoma—a review of treatment options beyond standard therapy,” Annals of Hematology, pp. 1–4, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Jagannath, A. Chanan-Khan, LT. Heffner et al., “BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed/refractory multiple myeloma,” Blood, vol. 118, no. 21, 2011. View at Google Scholar
  26. M. M. Al-Malki, J. J. Castillo, J. M. Sloan, and A. Re, “Hematopoietic cell transplantation for plasmablastic lymphoma: a review,” Biology of Blood and Marrow Transplantation, vol. 20, no. 12, pp. 1877–1884, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Cattaneo, H. Finel, G. McQuaker, E. Vandenberghe, G. Rossi, and P. Dreger, “Autologous hematopoietic stem cell transplantation for plasmablastic lymphoma: the European society for blood and marrow transplantation experience,” Biology of Blood and Marrow Transplantation, vol. 21, no. 6, pp. 1146-1147, 2015. View at Publisher · View at Google Scholar
  28. B. J. Chen, B. Chapuy, J. Ouyang et al., “PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies,” Clinical Cancer Research, vol. 19, no. 13, pp. 3462–3473, 2013. View at Publisher · View at Google Scholar · View at Scopus